Short answer
Apogee Therapeutics, Inc. (APGE) filed an 8-K current report with the SEC on August 11, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers), Item 5.07 (Submission of Matters to a Vote of Security Holders). All seven Apogee directors intend to resign upon completion of AbbVie merger.
Apogee Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.02 · Departure/Election of Directors or Officers
- All seven Apogee directors intend to resign upon completion of AbbVie merger
- Resignations apply to the board and applicable committees
- Apogee will become an indirect wholly owned AbbVie subsidiary after merger effectiveness
- Directors’ departures unrelated to disagreements over operations, policies or practices
Item 5.07 · Submission of Matters to a Vote of Security Holders
- Merger with AbbVie approved: 46,508,107 votes for versus 3,885 against
- 74.87% of outstanding shares represented, satisfying a key merger-closing condition
- Stockholder approval clears a major procedural hurdle for Apogee becoming AbbVie’s indirect wholly owned subsidiary
- Merger-related executive compensation rejected 27,123,259 to 19,323,605, but advisory vote is non-binding
- Adjournment unnecessary because sufficient merger votes were secured
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Apogee Therapeutics, Inc. 8-K filings
Get the next APGE 8-K as it lands
Follow APGE for push alerts, or ask the research agent what this filing means.